US Pharma MarketingMineralys makes money moves before looming hypertension approval
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug. It came with a $1 million upfront fee to the medicine Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator, Tanabe Pharma.
...
Source: Endpoints News